Safety of Sarcoplasmic Reticulum Ca2+-ATPase Gene Transfer by Intramyocardium Administration in Chronic Heart Failure Beagles / 中国康复理论与实践

@#ObjectiveTo assess the safety of intramyocardium injection of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) to rescue chronic heart failure beagles. MethodsThe heart failure beagles were assessed with myocardium enzymology, cAMP content of myocardium, myocardial oxygen consumption, arrhythmia, systemic inflammation factors, and the function of liver and kidney after SERCA2a gene transferred. ResultsThere were no increase of cAMP content, no more arrhythmia, myocardial oxygen consumption, no apparente systemic inflammation, and no injures to hepatic and renal function. ConclusionOverexpression of SERCA2a by intramyocardium injection is relatively safe.

Restoration of cardiac function in failing beagle hearts by recombinant adeno-associated viral gene transfer of sarcoplasmic reticulum Ca~(2+)-ATPase / 中国病理生理杂志

29.3% decrease in ejection fraction).4 of 11 were used as heart failure group(HF,n=4).9 HF beagles were randomized to receive either a recombinant adeno-associated viral carrying the SERCA2a gene(HF+SERC A2a,n=5) or the reporter gene enhanced green fluorescent protein(HF+EGFP,n=4) by thoracotomy.All HF beagles paced by 180 beats/min in order to maintain failing state.Thirty days after infection,parameters of systolic and diastolic function were measured by doppler echocardiography and hemodynamic monitor in all beagles.RESULTS:At 30 days after gene transfer,symptoms of HF+SERCA2a dogs improved.Echocardiogram parameters were superior to those in HF+EGFP group(P